Key facts
- This page summarizes David Robert Bogart's Form 3 filing for Conexeu Sciences Inc..
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 11 May 2026, 18:55.
David Robert Bogart - 11 May 2026 Form 3 Insider Report for Conexeu Sciences Inc.
- Reporting relationship
- Director
- Issuer ticker
- CNXU on Nasdaq
- Reported as of
- 11 May 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ David Bogart
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
David Robert Bogart filed Form 3 for Conexeu Sciences Inc. on 11 May 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002128417
Primary reporting owner
Bogart David Robert
- Relationship
- Director
- Address
- 50 WEST LIBERTY STREET, SUITE 880, RENO
- Signature
- /s/ David Bogart
- Signature date
- 11 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
No ticker
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,062,500
- Date
- 11 May 2026
- Ownership
- Direct
No ticker
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 431,250
- Date
- 11 May 2026
- Ownership
- By 0865546 B.C. Ltd.
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No ticker
holding
Derivative
Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 11 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $0.4000
- Footnotes
- F2
No ticker
holding
Derivative
Performance Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 11 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,000,000
- Exercise price
- $0.001000
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Held by 0865546 B.C. Ltd., over which the Reporting Person has sole voting and dispositive power.
Footnote F2
On June 9, 2025, the Issuer granted to the Reporting Person 50,000 stock options with an exercise price of $0.40 for 60 months from the date of issuance and that vested immediately.
Footnote F3
The Performance Warrants were granted on June 5, 2025 and have an exercise price of $0.001 and a term of 5 years. 250,000 Performance Warrants have vested. The remainder of the Performance Warrants will vest and be exercisable upon the following milestone events: (i) 250,000 Performance Warrants upon the Issuer's shares of common stock being listed on a recognized stock exchange in North America; (ii) 250,000 Performance Warrants upon the Issuer's listed shares of common stock trading for at least 20 consecutive trading days at a market capitalization of $80,000,000 or greater in the currency of the recognized stock exchange in North America on which the shares of common stock are listed; and (iii) 250,000 Performance Warrants upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration.